Bone Therapeutics Information on the total number of voting rights and shares

 

the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 11 April 2018 following the conversion of convertible bonds issued on the private placement on 7 March 2017. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital on 7 March 2018

EUR 15,873,555

Total number of shares with voting rights on 7 March 2018

7,415,427

Total number of new shares issued on 11 April 2018

44,333

 

Total amount of share capital on 11 April 2018

EUR 15,968,428

Total number of shares with voting rights on 11 April 2018 (a)

7,459,760

Total number of voting rights (denominator) on 11 April 2018

7,459,760

Total number of attributed warrants (2)

167,300

Total number of convertible bonds outstanding

335

Total number of bond warrants outstanding

4,887

Total number of shares with voting rights following the exercise of the bond warrants, the conversion of the convertible bonds and the attributed warrants (1) (b)

1,632,080

Total number of diluted shares (= (a) + (b))

9,091,840

 

(1) Based on the conversion price of EUR 8.9126 (92% of the Volume-Weighted-Averaged-Price of Bone Therapeutics on 11 April 2018)

(2) A net decrease of 16,500 attributed warrants as 32,500 warrants became void and 16,000 warrants were granted under the existing warrant plans.

Note

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics' technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company's primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?